SG1827
/ Sumgen Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
June 27, 2025
CSG-1827-101: An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=122 | Active, not recruiting | Sponsor: Hangzhou Sumgen Biotech Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial primary completion date: Apr 2025 ➔ Jun 2026
Enrollment closed • Trial primary completion date • Solid Tumor
March 12, 2025
CSG-1827-101: An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=122 | Recruiting | Sponsor: Hangzhou Sumgen Biotech Co., Ltd. | Trial completion date: Mar 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2024 ➔ Apr 2025
Trial completion date • Trial primary completion date • Oncology • Solid Tumor
October 24, 2024
An umbrella trial (RECHALLENGE) to evaluate the safety and preliminary efficacy of combination or sequential immunotherapy in advanced solid tumor patients after disease progression in clinical trials.
(ESMO-IO 2024)
- P1/2 | "Those who progressed on drug A (SG1827, CD80 fusion protein) or B (ABO2011, mRNA vaccine encoding IL-12) will receive their respective drug with Triplimab at 3 mg/kg IV every two weeks, continuing their prior treatment regimen (cohort A, B). Secondary endpoints include efficacy assessments like objective response rate, disease control rate, duration of response, progression-free survival, and overall survival. This trial began in May 2024 and has enrolled 3 patients at the time of submission."
Clinical • Metastases • Oncology • Solid Tumor • CD80 • IL12A
October 10, 2023
CSG-1827-101: An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=122 | Recruiting | Sponsor: Hangzhou Sumgen Biotech Co., Ltd.
Metastases • New P1 trial • Oncology • Solid Tumor • IFNG • IL10 • IL6 • TNFA
1 to 4
Of
4
Go to page
1